Opinion|Videos|February 18, 2025

Future Directions of BCG-Unresponsive NMIBC Management

A panelist discusses how urologists considering newer treatment modalities for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) should be encouraged by positive clinical trial data while ensuring proper training, patient selection, and establishment of treatment protocols in their practice.

Episodes in this series
  • What advice do you have for urologists considering the adoption of newer treatment modalities for BCG-unresponsive NMIBC, especially in light of the positive clinical trial data?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more